Page 1

ANTERIS ASX ANNOUNCEMENT 26 August 2021 APPENDIX 4D AND HALF YEARLY FINANCIAL REPORT Anteris Technologies Ltd ( ASX : AVR ) ( Anteris or the Company ) releases its Appendix 4D - Half Yearly Financial Report and commentary for the period ended 30 June 2021 . HIGHLIGHTS : . • Significant progress delivered across its entire clinical development program , highlighting the superiority of its three core technologies – ADAPTⓇ , DurAVRⓇ and ComASUR ™ Positive data generated from ADAPTⓇ anti - calcification study demonstrating superior anti- calcification attributes compared to competitor tissues Milestone achievements in the ongoing development of AVR's ComASUR ™ catheter delivery system with working prototypes successfully deployed in multiple tests No evidence of calcification in AVR's Proof of Concept animal study on the viability of ADAPTⓇ treated conduits in the carotid artery Anteris delivered total revenue of $ 3.1M and successfully raised $ 9M from sophisticated investors subsequent to the half Operational overview Anteris continued to materially progress its ADAPTⓇ and TAVR development program which included the advancement of all ongoing clinical and pre - clinical studies . The Company also made major progress towards its planned US FDA submission and approval of the TAVR clinical study scheduled later this year . Anteris delivered positive results from its anti - calcification study where its ADAPTⓇ treated tissue demonstrated superior anti - calcification attributes compared to tissues used in competitor valves . Based on these results , the Company will initiate a further study comparing its ADAPTⓇ tissue with both Medtronic's AOATM and Edwards Life Science's ResiliaⓇ , which is expected to start later this year . Anteris also significantly advanced the development of its ComASUR ™ catheter delivery system with working prototypes successfully deployed in multiple tests . The delivery system allows for precise placement of the valve , a highly sought - after functionality which is currently unavailable in the market . The Company's Proof of Concept ( POC ) animal study which aimed to test the viability of ADAPTⓇ treated conduits in the carotid artery also delivered positive outcomes , highlighting conduits treated with ADAPTⓇ tissue technology demonstrated no evidence of calcification . This is a milestone achievement for the Company and a major step towards ADAPTⓇ treated prosthetic conduits being utilised in CABG ( coronary artery bypass graft ) surgeries . Anteris Technologies Ltd Registered Office : Toowong Tower , Suite 302 , Level 3 , 9 Sherwood Rd , Toowong , Queensland , 4066 Customer Service T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com Brisbane ▪ Minneapolis ▪Geneva ▪ Malaga ADAPT for life